Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchì A, Martinetti A, Sottotetti E, Arata A, Corsetto P, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: sottotetti e. Cell Metab. 2024 Dec 17:S1550-4131(24)00450-9. doi: 10.1016/j.cmet.2024.11.004. Online ahead of print. Cell Metab. 2024. PMID: 39694040
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. Niger M, et al. Among authors: sottotetti e. BMC Cancer. 2024 May 6;24(1):563. doi: 10.1186/s12885-024-12328-0. BMC Cancer. 2024. PMID: 38711003 Free PMC article. No abstract available.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. Niger M, et al. Among authors: sottotetti e. BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6. BMC Cancer. 2024. PMID: 38589856 Free PMC article. Clinical Trial.
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S, Khan K, Fontana E, Angerilli V, Delrieux M, Nava Rodrigues D, Procaccio L, Rao S, Watkins D, Starling N, Chau I, Braconi C, Fotiadis N, Begum R, Guppy N, Howell L, Valenti M, Cribbes S, Kolozsvari B, Kirkin V, Lonardi S, Ghidini M, Passalacqua R, Elghadi R, Magnani L, Pinato DJ, Di Maggio F, Ghelardi F, Sottotetti E, Vetere G, Ciracì P, Vlachogiannis G, Pietrantonio F, Cremolini C, Cortellini A, Loupakis F, Fassan M, Valeri N. Hedayat S, et al. Among authors: sottotetti e. Clin Cancer Res. 2024 May 15;30(10):2140-2159. doi: 10.1158/1078-0432.CCR-23-2748. Clin Cancer Res. 2024. PMID: 38376926 Clinical Trial.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. Manglaviti S, et al. Among authors: sottotetti e. Lung Cancer. 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub 2023 Oct 29. Lung Cancer. 2023. PMID: 37918061
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchì A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: sottotetti e. Int J Cancer. 2024 Jan 1;154(1):114-123. doi: 10.1002/ijc.34701. Epub 2023 Aug 24. Int J Cancer. 2024. PMID: 37615485 Free article.
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
Marmorino F, Prisciandaro M, Giordano M, Ortolan E, Crucitta S, Manca P, Antoniotti C, Valenti MM, Danesi R, Conca V, Mazzoli G, Boccaccino A, Carullo M, Martinetti A, Sottotetti E, Masi G, Sposito C, Zaffaroni N, Milione M, Fontanini G, Del Re M, Pietrantonio F, Cremolini C. Marmorino F, et al. Among authors: sottotetti e. JCO Precis Oncol. 2022 Nov;6:e2200244. doi: 10.1200/PO.22.00244. JCO Precis Oncol. 2022. PMID: 36356286
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
Fucà G, Lecchi M, Ciniselli CM, Ottini A, Spagnoletti A, Mazzeo L, Morelli D, Frati P, Stroscia M, Ebrahem E, Sottotetti E, Galli G, D'Elia MG, Lobefaro R, Ducceschi M, Di Guardo L, Bhoori S, Provenzano S, Platania M, Niger M, Colombo E, Nichetti F, Duca M, Rivoltini L, Mortarini R, Baili P, Apolone G, de Braud F, Verderio P, Damian S. Fucà G, et al. Among authors: sottotetti e. Ther Adv Med Oncol. 2022 Jul 27;14:17588359221108687. doi: 10.1177/17588359221108687. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923922 Free PMC article.
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.
Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F. Ambrosini M, et al. Among authors: sottotetti e. JCO Precis Oncol. 2022 Apr;6(1):e2200015. doi: 10.1200/PO.22.00015. JCO Precis Oncol. 2022. PMID: 35476549 Free PMC article.
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
Manca P, Corallo S, Lonardi S, Fucà G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smiroldo V, Ratti M, Murialdo R, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, Morano F, Pietrantonio F. Manca P, et al. Among authors: sottotetti e. Br J Cancer. 2022 Feb;126(3):449-455. doi: 10.1038/s41416-021-01591-8. Epub 2021 Nov 22. Br J Cancer. 2022. PMID: 34811502 Free PMC article. Clinical Trial.
27 results